Cristal Therapeutics is a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform. CriPec®-based products have the potential to optimize the efficacy/safety balance, thus offering improved disease treatment. The Company’s lead product, CPC634, is in clinical Phase 2 development for the treatment of solid tumours. The Company has several other products in preclinical development focused on the treatment of cancer. Cristal Therapeutics has a number of partnerships with large pharma and mature biotech companies. Cristal Therapeutics is a private company that has raised over € 20M equity financing to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.